ClinicalTrials.gg
RecruitingNCT07784387BRITEUpdated Aug 28, 2026

A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

An observational study in Urinary Bladder Neoplasms, sponsored by Janssen-Cilag Farmaceutica Ltda.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson — 2 open to participants now, 5 under way, 2 of them phase 3. Urinary Bladder Neoplasms · Johnson & Johnson.

Started
2026
with 1 other
Observational
2 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 12th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

2 of the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.

03

Conditions studied

  • Urinary Bladder Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes the participants from Portuguese hospitals that treat and manage High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bladder cancer diagnosis between January 1, 2016 and December 31, 2020
  • Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue)
  • Minimal follow-up time of 5 years unless there is premature death event

Exclusion criteria

Exclusion criteria:

  • Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1
  • History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC
  • Participation in any interventional clinical trial during the observation period
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • HR-NMIBC Participants: Portuguese Routine Practice

    Participants diagnosed with high-risk non-muscle-Invasive bladder cancer (HR-NMIBC) in Portugal between January 1, 2016 and December 31, 2020, with tumor stage N0/x and M0/x and one of the following: Tis (primary CIS), TaG3/HG, or T1 will be enrolled. Demographic and clinical information will be gathered from both electronic and paper records for each participant. Only data available within routine clinical practice from the diagnosis until, at least, 5 years after diagnosis will be collected in this study. No drug will be administered as a part of this study.

06

What researchers measure

Primary outcomes

  1. Treatment Patterns: Type of Therapeutic Approach

    Number of participants receiving different types of therapeutic approach including bacillus calmette-guerin (BCG) therapy, chemotherapy, radiotherapy, immunotherapy, or targeted therapy will be reported.

    Time frame: Up to 5 years

  2. Treatment Patterns: Type of Surgery

    Number of participants undergoing different types of surgery, including transurethral resection of the bladder tumor (TURBT), repeat TURBT or cystectomy will be reported.

    Time frame: Up to 5 years

  3. Treatment Patterns by Subpopulation: Tumor Stage

    Number of participants by tumor stage will be reported.

    Time frame: Up to 5 years

  4. Treatment Patterns by Subpopulation: Histology

    Number of participants by histology will be reported.

    Time frame: Up to 5 years

  5. Treatment Patterns by Subpopulation: Line of Therapy

    Number of participants by line of therapy will be reported,

    Time frame: Up to 5 years

Secondary outcomes

  1. Total Number of BCG Doses Administered

    Total number of BCG doses administered will be reported.

    Time frame: Up to 5 years

  2. Percentage of Participants With BCG Non-Responsive Disease

    Percentage of participants with BCG non-responsive disease will be reported. This is defined as being one of the following: a) Persistent or recurrent carcinoma in situ (CIS) alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy (defined as at least 5 of 6 induction doses, plus at least 2 of 3 maintenance doses or a second induction). b) Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy. c) T1 high-grade disease at the first evaluation following an induction BCG course.

    Time frame: Up to 5 years

  3. Reasons for BCG Interruption

    Number of participants with reasons for BCG interruption will be reported.

    Time frame: Up to 5 years

  4. Therapy Choice at Recurrence

    Therapy choice at recurrence for participants will be reported.

    Time frame: Up to 5 years

  5. Recurrence-Free Survival (RFS)

    RFS is defined as the time from the date of first treatment initiation for high-risk non-muscle invasive bladder cancer (HR-NMIBC) to the first documented recurrence of high-risk disease, death due to any cause, or censoring, whichever occurs first.

    Time frame: Up to 5 years

  6. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of first treatment initiation for HR-NMIBC to the first documentation of disease progression, death from any cause, or censoring, whichever occurs first.

    Time frame: Up to 5 years

  7. Overall Survival (OS)

    OS is defined as the time from the date of first treatment initiation for HR-NMIBC to death from any cause or censoring, whichever occurs first.

    Time frame: Up to 5 years

  8. Metastasis-Free Survival (MFS)

    MFS is defined as the time from the date of first treatment initiation for HR-NMIBC to the occurrence of distant metastasis, death from any cause, or censoring, whichever occurs first.

    Time frame: Up to 5 years

  9. Time to Next Treatment (TTNT)

    TTNT is defined as the time from the date of first treatment initiation for HR-NMIBC to the initiation of the next line of treatment or censoring.

    Time frame: Up to 5 years

  10. Time on Treatment (TOT)

    TOT is defined as the duration between the first and last administration of the treatment.

    Time frame: Up to 5 years

  11. Complete Response Rate (CR)

    Complete response is defined as the absence of detectable bladder cancer at 6 months after completion of treatment, as confirmed by cystoscopic evaluation and optionally complemented by urine cytology.

    Time frame: Up to 5 years

  12. Number and Type of Healthcare Resource Utilization Related to HR-NMIBC

    Number and type of healthcare resource utilization related to HR-NMIBC, including procedures, hospitalizations and outpatient visits will be reported.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at https://www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 25, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Feb 15, 2028
CompletionEst.
Feb 25, 2028
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784387
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Aug 25, 2026
Primary completion
Feb 15, 2028 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Aug 28, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen-Cilag Farmaceutica Ltda. Clinical Trial
study director · Janssen-Cilag Farmaceutica Ltda.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion